Amyloid Beta-peptide (25-35) (human)
(Synonyms: BETA-淀粉样蛋白片断25-35,Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met ) 目录号 : GP10082
淀粉样蛋白β肽(Aβ) (25-35)(human)是阿尔茨海默病淀粉样蛋白β肽的片段，具有神经毒性作用。
Cas No.:131602-53-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Amyloid beta(Aβ)-peptide (25-35) (human) is an fragment of Alzheimer's Amyloid beta peptide which is commonly found in the brains of people with Alzheimer's disease (AD) and is a major component of Alzheimer's amyloid plaques[1-3]. Amyloid beta-peptide (25-35) (human) is considered a functional domain of Aβ due to its neurotoxic effects, and it is the bioactive region of beta-amyloid[4].
Amyloid beta-peptide (25-35) (human) treatment (20 μM, 6 hours) activated tau protein kinase I/glycogen synthase kinase-3beta (TPKI/GSK-3beta) in primary culture of hippocampal neurons [5]. The Amyloid beta-peptide (25-35) (human) (100nM, 1μM, 10μM, or 30μM) reduces the viability of cultured cerebral cortical rat neurons [6]. Amyloid beta-peptide (25-35) (human) (10μM) increased the amplitude of excitatory responses produced by local iontophoretic applications of glutamate and NMDA [7]. Treatment of PC12 cells with 20 μM of Amyloid beta-peptide (25-35) (human) for 24 h induced cytotoxicity as the cell viability was reduced to 67% of the control value (100%)[8].
A single intracerebroventricular (i.c.v.) injection of Amyloid beta-peptide (25-35) (human) (15 nmol/5 μl; i.c.v.;8days) at a dose of 15 nmol/rat induced a marked decrease in latency in step-through passive avoidance task[9].
References:
[1]. Nalbantoglu J. Beta-amyloid protein in Alzheimer's disease. Can J Neurol Sci. 1991 Aug;18(3 Suppl):424-7. doi: 10.1017/s0317167100032595. PMID: 1933692.
[2]. Rush DK, Aschmies S, et,al. Intracerebral beta-amyloid(25-35) produces tissue damage: is it neurotoxic? Neurobiol Aging. 1992 Sep-Oct;13(5):591-4. doi: 10.1016/0197-4580(92)90061-2. PMID: 1281289.
[3]. Mattson MP, Cheng B, et,al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992 Feb;12(2):376-89. doi: 10.1523/JNEUROSCI.12-02-00376.1992. PMID: 1346802; PMCID: PMC6575616.
[4]. D'Errico, G; Vitiello, G; et,al. Interaction between Alzheimer's A(25-35) peptide and phospholipid bilayers: The role of cholesterol. Biochimica. Biophys. Acta (BBA) – Biomembr., 2008, 1778, 2710-2716.
[5]. Takashima A, Honda T, et,al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998 Aug;31(4):317-23. doi: 10.1016/s0168-0102(98)00061-3. PMID: 9809590.
[6]. Wang Y, Liu L, et,al. Mechanism of soluble beta-amyloid 25-35 neurotoxicity in primary cultured rat cortical neurons. Neurosci Lett. 2016 Apr 8;618:72-76. doi: 10.1016/j.neulet.2016.02.050. Epub 2016 Mar 3. PMID: 26940239.
[7]. Carette B, Poulain P, et,al. Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons. Neurosci Lett. 1993 Mar 5;151(1):111-4. doi: 10.1016/0304-3940(93)90059-t. PMID: 8385758.
[8]. Xian YF, Lin ZX, Mao QQ, Ip SP, Su ZR, Lai XP. Protective effect of isorhynchophylline against β-amyloid-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol. 2012 Apr;32(3):353-60. doi: 10.1007/s10571-011-9763-5. Epub 2011 Nov 1. PMID: 22042506.
[9]. Yamaguchi Y, Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol. 2001 Feb 2;412(3):265-72. doi: 10.1016/s0014-2999(01)00730-0. PMID: 11166290.
淀粉样蛋白β (Aβ)肽(25-35)(human)是阿尔茨海默病淀粉样蛋白β肽的片段，通常存在于阿尔茨海默病(AD)患者的大脑中，是阿尔茨海默病淀粉样斑块的主要成分[1-3]。淀粉样蛋白β 肽(25-35)(human)由于其神经毒性作用被认为是Aβ的一个功能域，它是β -淀粉样蛋白的生物活性区域[4]。
淀粉样蛋白β 肽(25-35)(human)处理(20 μM, 6h)激活了海马神经元原代培养的tau蛋白激酶I/糖原合成酶激酶3 β(TPKI/GSK-3beta) [5]。淀粉样蛋白β 肽(25-35)(human) (100nM, 1μM, 10μM或30μM)降低培养的大鼠大脑皮质神经元的活力[6]。淀粉样蛋白β 肽(25-35)(human) (10μM) 增加了局部应用谷氨酸和NMDA产生的兴奋反应的振幅[7]。20 μM淀粉样蛋白β 肽(25-35)(human) 处理PC12细胞24 h后，细胞活力降至对照组(100%)的67%，产生细胞毒性[8]。
淀粉样蛋白β 肽(25-35)(human) (15 nmol/5 μl; i.c.v.;8days )可显著降低步进被动回避任务的潜伏期[9]。
|
细胞实验 [1]: |
|
|
细胞系 |
PC12 cells |
|
实验方法 |
聚集态Amyloid Beta-peptide (25-35) (human)的制备：将Amyloid Beta-peptide (25-35) (human)溶于去离子水中，浓度为1mM，过滤除菌，37℃孵育4天，诱导聚集，-20℃保存备用。 将细胞以2个×104细胞/孔的密度接种到96孔培养板上。37℃稳定48h后，游离血清培养基中加入终浓度为20 μM的 Amyloid-β-(25-35)再培养24h。 |
|
实验条件 |
20 μM; 24 hours |
|
应用 |
20 μM Amyloid-β-(25-35)处理PC12细胞24 h后，细胞活力降至对照组(100%)的67%，产生细胞毒性。 |
|
动物实验 [2]: |
|
|
动物品系 |
Sprague-Dawley的雄性老鼠 |
|
实验方法 |
以15 nmol/5 μl剂量注射 Amyloid Beta-peptide (25-35) (human) 8 天后，测定足电刺激下大鼠的退缩、发声和跳跃阈值。 |
|
实验条件 |
15 nmol/5 μl; i.c.v.;8days |
|
应用 |
单次脑室内注射15 nmol/大鼠 剂量的 Amyloid Beta-peptide (25-35) (human) 可显著降低步进被动回避任务的潜伏期。 |
|
References: [1]. Xian YF, Lin ZX, et,al. Protective effect of isorhynchophylline against β-amyloid-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol. 2012 Apr;32(3):353-60. doi: 10.1007/s10571-011-9763-5. Epub 2011 Nov 1. PMID: 22042506. [2]. Yamaguchi Y, Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol. 2001 Feb 2;412(3):265-72. doi: 10.1016/s0014-2999(01)00730-0. PMID: 11166290. |
|
| Cas No. | 131602-53-4 | SDF | |
| 别名 | BETA-淀粉样蛋白片断25-35,Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met | ||
| 化学名 | Amyloid Beta-peptide (25-35) (human) | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(C(C)CC)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)CN | ||
| 分子式 | C45H81N13O14S | 分子量 | 1060.27 |
| 溶解度 | ≥ 106mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9432 mL | 4.7158 mL | 9.4316 mL |
| 5 mM | 0.1886 mL | 0.9432 mL | 1.8863 mL |
| 10 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet